ES2348607T3 - Procedimiento de detección de patogenos con uso de balizas moleculares. - Google Patents

Procedimiento de detección de patogenos con uso de balizas moleculares. Download PDF

Info

Publication number: ES2348607T3
Authority: ES; Spain
Prior art keywords: probes; sequence; probe; dna; nucleic acid
Prior art date: 2005-11-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES06808556T

Other languages

English (en)

Spanish (es)

Inventor

Csaba Jeney

Tibor Takacs

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genoid Kft

Original Assignee

Genoid Kft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-15

Filing date

2006-11-15

Publication date

2010-12-09

2006-11-15 Application filed by Genoid Kft filed Critical Genoid Kft

2010-12-09 Application granted granted Critical

2010-12-09 Publication of ES2348607T3 publication Critical patent/ES2348607T3/es

Status Active legal-status Critical Current

2026-11-15 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title claims abstract description 146
244000052769 pathogen Species 0.000 title claims abstract description 55
238000001514 detection method Methods 0.000 title claims description 54
239000000523 sample Substances 0.000 claims abstract description 243
150000007523 nucleic acids Chemical class 0.000 claims abstract description 74
108020004707 nucleic acids Proteins 0.000 claims abstract description 64
102000039446 nucleic acids Human genes 0.000 claims abstract description 64
230000001717 pathogenic effect Effects 0.000 claims abstract description 45
230000000295 complement effect Effects 0.000 claims abstract description 34
238000009396 hybridization Methods 0.000 claims abstract description 29
230000008859 change Effects 0.000 claims abstract description 12
241000701806 Human papillomavirus Species 0.000 claims description 163
230000003321 amplification Effects 0.000 claims description 60
238000003199 nucleic acid amplification method Methods 0.000 claims description 60
230000027455 binding Effects 0.000 claims description 16
238000003752 polymerase chain reaction Methods 0.000 claims description 16
208000019802 Sexually transmitted disease Diseases 0.000 claims description 15
230000008569 process Effects 0.000 claims description 15
241000700605 Viruses Species 0.000 claims description 9
210000003679 cervix uteri Anatomy 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
238000002844 melting Methods 0.000 claims description 8
230000008018 melting Effects 0.000 claims description 8
238000001574 biopsy Methods 0.000 claims description 7
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
230000002380 cytological effect Effects 0.000 claims description 4
210000004392 genitalia Anatomy 0.000 claims description 4
210000000867 larynx Anatomy 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
210000002700 urine Anatomy 0.000 claims description 3
102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 2
108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 2
210000000436 anus Anatomy 0.000 claims description 2
210000004369 blood Anatomy 0.000 claims description 2
239000008280 blood Substances 0.000 claims description 2
210000001352 masseter muscle Anatomy 0.000 claims description 2
210000002307 prostate Anatomy 0.000 claims description 2
210000003491 skin Anatomy 0.000 claims description 2
239000000758 substrate Substances 0.000 claims description 2
229940035893 uracil Drugs 0.000 claims description 2
210000003905 vulva Anatomy 0.000 claims description 2
108020004414 DNA Proteins 0.000 description 163
239000013615 primer Substances 0.000 description 149
238000002680 cardiopulmonary resuscitation Methods 0.000 description 43
238000006243 chemical reaction Methods 0.000 description 39
241000341655 Human papillomavirus type 16 Species 0.000 description 22
239000000370 acceptor Substances 0.000 description 22
239000002773 nucleotide Substances 0.000 description 20
125000003729 nucleotide group Chemical group 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 20
150000003557 thiazoles Chemical class 0.000 description 20
206010008342 Cervix carcinoma Diseases 0.000 description 17
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 17
210000004027 cell Anatomy 0.000 description 17
201000010881 cervical cancer Diseases 0.000 description 17
238000003556 assay Methods 0.000 description 16
230000003612 virological effect Effects 0.000 description 15
239000000975 dye Substances 0.000 description 14
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 12
241001631646 Papillomaviridae Species 0.000 description 12
230000003993 interaction Effects 0.000 description 12
238000013461 design Methods 0.000 description 11
230000003902 lesion Effects 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000035945 sensitivity Effects 0.000 description 11
108091093088 Amplicon Proteins 0.000 description 10
208000009608 Papillomavirus Infections Diseases 0.000 description 10
230000005284 excitation Effects 0.000 description 10
206010028980 Neoplasm Diseases 0.000 description 8
108700026244 Open Reading Frames Proteins 0.000 description 8
238000013459 approach Methods 0.000 description 8
238000003753 real-time PCR Methods 0.000 description 8
239000012472 biological sample Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
238000009595 pap smear Methods 0.000 description 7
239000003155 DNA primer Substances 0.000 description 6
241000239226 Scorpiones Species 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
208000019065 cervical carcinoma Diseases 0.000 description 6
238000001506 fluorescence spectroscopy Methods 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
238000011002 quantification Methods 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
241000894007 species Species 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
108091034117 Oligonucleotide Proteins 0.000 description 5
101150053549 cni gene Proteins 0.000 description 5
230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 5
231100000590 oncogenic Toxicity 0.000 description 5
230000002246 oncogenic effect Effects 0.000 description 5
238000005070 sampling Methods 0.000 description 5
238000013518 transcription Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
239000002253 acid Substances 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000010354 integration Effects 0.000 description 4
150000004893 oxazines Chemical class 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
201000010153 skin papilloma Diseases 0.000 description 4
239000000243 solution Substances 0.000 description 4
-1 stilbenes indoles Chemical class 0.000 description 4
230000035897 transcription Effects 0.000 description 4
150000000183 1,3-benzoxazoles Chemical class 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
208000009458 Carcinoma in Situ Diseases 0.000 description 3
206010008263 Cervical dysplasia Diseases 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
101710125507 Integrase/recombinase Proteins 0.000 description 3
108010006785 Taq Polymerase Proteins 0.000 description 3
229910052771 Terbium Inorganic materials 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
208000009956 adenocarcinoma Diseases 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000004590 computer program Methods 0.000 description 3
239000013068 control sample Substances 0.000 description 3
238000012937 correction Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000695 excitation spectrum Methods 0.000 description 3
238000003205 genotyping method Methods 0.000 description 3
210000002510 keratinocyte Anatomy 0.000 description 3
238000005259 measurement Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000002688 persistence Effects 0.000 description 3
230000037452 priming Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
238000010186 staining Methods 0.000 description 3
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 3
238000012360 testing method Methods 0.000 description 3
HIYWOHBEPVGIQN-UHFFFAOYSA-N 1h-benzo[g]indole Chemical class C1=CC=CC2=C(NC=C3)C3=CC=C21 HIYWOHBEPVGIQN-UHFFFAOYSA-N 0.000 description 2
PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
LAXVMANLDGWYJP-UHFFFAOYSA-N 2-amino-5-(2-aminoethyl)naphthalene-1-sulfonic acid Chemical class NC1=CC=C2C(CCN)=CC=CC2=C1S(O)(=O)=O LAXVMANLDGWYJP-UHFFFAOYSA-N 0.000 description 2
SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 2
206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 2
206010059313 Anogenital warts Diseases 0.000 description 2
108020001019 DNA Primers Proteins 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
101150082674 E2 gene Proteins 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
241000722343 Human papillomavirus types Species 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
150000001251 acridines Chemical class 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
150000001454 anthracenes Chemical class 0.000 description 2
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
229940111121 antirheumatic drug quinolines Drugs 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
150000005130 benzoxazines Chemical class 0.000 description 2
239000000298 carbocyanine Substances 0.000 description 2
125000005606 carbostyryl group Chemical group 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
201000006662 cervical adenocarcinoma Diseases 0.000 description 2
208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
238000013480 data collection Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000000295 emission spectrum Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000021145 human papilloma virus infection Diseases 0.000 description 2
230000006872 improvement Effects 0.000 description 2
201000004933 in situ carcinoma Diseases 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000020082 intraepithelial neoplasia Diseases 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
150000002790 naphthalenes Chemical class 0.000 description 2
102000027450 oncoproteins Human genes 0.000 description 2
108091008819 oncoproteins Proteins 0.000 description 2
230000008520 organization Effects 0.000 description 2
150000002916 oxazoles Chemical class 0.000 description 2
210000003899 penis Anatomy 0.000 description 2
150000002979 perylenes Chemical class 0.000 description 2
QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical class [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
150000004032 porphyrins Chemical class 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
150000003220 pyrenes Chemical class 0.000 description 2
150000003222 pyridines Chemical class 0.000 description 2
238000003908 quality control method Methods 0.000 description 2
238000006862 quantum yield reaction Methods 0.000 description 2
150000003248 quinolines Chemical class 0.000 description 2
208000001307 recurrent respiratory papillomatosis Diseases 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
150000003873 salicylate salts Chemical class 0.000 description 2
238000007790 scraping Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
235000021286 stilbenes Nutrition 0.000 description 2
238000005496 tempering Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
238000001429 visible spectrum Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical class [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 1
ZWONWYNZSWOYQC-UHFFFAOYSA-N 5-benzamido-3-[[5-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C(N=NC2=CC(NC3=NC(NC4=CC=C(C=C4)S(O)(=O)=O)=NC(Cl)=N3)=CC=C2S(O)(=O)=O)C(=CC2=C1C(NC(=O)C1=CC=CC=C1)=CC(=C2)S(O)(=O)=O)S(O)(=O)=O ZWONWYNZSWOYQC-UHFFFAOYSA-N 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
206010051999 Anogenital dysplasia Diseases 0.000 description 1
208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
JFDIFVIYJDSOHI-UHFFFAOYSA-N B1N2CC=CC2=CC2=CC=CN12 Chemical class B1N2CC=CC2=CC2=CC=CN12 JFDIFVIYJDSOHI-UHFFFAOYSA-N 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
101150071673 E6 gene Proteins 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108091092566 Extrachromosomal DNA Proteins 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
108020003587 HPV DNA Probes Proteins 0.000 description 1
239000003347 HPV DNA probe Substances 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 description 1
241000701828 Human papillomavirus type 11 Species 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
206010024434 Lichen sclerosus Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101710157639 Minor capsid protein Proteins 0.000 description 1
101100521055 Mus musculus Prl7d1 gene Proteins 0.000 description 1
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
101710189720 Porphobilinogen deaminase Proteins 0.000 description 1
102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 1
101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
101710136297 Protein VP2 Proteins 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
238000001069 Raman spectroscopy Methods 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
241000907663 Siproeta stelenes Species 0.000 description 1
208000032124 Squamous Intraepithelial Lesions Diseases 0.000 description 1
208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
241000589499 Thermus thermophilus Species 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
238000010420 art technique Methods 0.000 description 1
150000001545 azulenes Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
150000001556 benzimidazoles Chemical class 0.000 description 1
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
ONTQJDKFANPPKK-UHFFFAOYSA-L chembl3185981 Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C=C1N=NC1=CC(S([O-])(=O)=O)=C(C=CC=C2)C2=C1O ONTQJDKFANPPKK-UHFFFAOYSA-L 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002573 colposcopy Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000010276 construction Methods 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
150000004775 coumarins Chemical class 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
150000005182 dinitrobenzenes Chemical class 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
KPBGWWXVWRSIAY-UHFFFAOYSA-L disodium;2',4',5',7'-tetraiodo-6-isothiocyanato-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C2=CC=C(N=C=S)C=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KPBGWWXVWRSIAY-UHFFFAOYSA-L 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000004920 epithelial cell of skin Anatomy 0.000 description 1
230000009841 epithelial lesion Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
235000021384 green leafy vegetables Nutrition 0.000 description 1
230000036541 health Effects 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 1
ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000011880 melting curve analysis Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
231100001222 nononcogenic Toxicity 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical group NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
238000000675 plasmon resonance energy transfer Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000002987 primer (paints) Substances 0.000 description 1
230000004853 protein function Effects 0.000 description 1
238000001273 protein sequence alignment Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011897 real-time detection Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000754 repressing effect Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
229940043267 rhodamine b Drugs 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
108010068698 spleen exonuclease Proteins 0.000 description 1
230000007480 spreading Effects 0.000 description 1
208000020077 squamous cell intraepithelial neoplasia Diseases 0.000 description 1
230000010097 squamous lesion Effects 0.000 description 1
150000001629 stilbenes Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
208000024719 uterine cervix neoplasm Diseases 0.000 description 1
230000007733 viral latency Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000006490 viral transcription Effects 0.000 description 1
230000010464 virion assembly Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

ES06808556T 2005-11-15 2006-11-15 Procedimiento de detección de patogenos con uso de balizas moleculares. Active ES2348607T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0523250		2005-11-15
GB0523250A GB0523250D0 (en)	2005-11-15	2005-11-15	Method
US737006P		2005-11-15

Publications (1)

Publication Number	Publication Date
ES2348607T3 true ES2348607T3 (es)	2010-12-09

Family

ID=35516956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES06808556T Active ES2348607T3 (es)	2005-11-15	2006-11-15	Procedimiento de detección de patogenos con uso de balizas moleculares.

Country Status (7)

Country	Link
CN (1)	CN101360833A (pt)
BR (1)	BRPI0620507A2 (pt)
DK (1)	DK1844164T3 (pt)
ES (1)	ES2348607T3 (pt)
GB (1)	GB0523250D0 (pt)
NZ (1)	NZ568290A (pt)
PT (1)	PT1844164E (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102732605B (zh) *	2011-09-21	2014-08-20	河北农业大学	一种用于检测羊bmpr-ib基因多态性的pcr试剂盒
WO2018059581A1 (zh) *	2016-09-30	2018-04-05	广州易活生物科技有限公司	一种基于efirm技术的hpv病毒分型检测的探针、试剂盒及应用
CN117890582B (zh) *	2023-12-21	2025-01-21	南京迪安医学检验所有限公司	一种单纯疱疹病毒检测试剂盒及其检测方法

2005
- 2005-11-15 GB GB0523250A patent/GB0523250D0/en not_active Ceased
2006
- 2006-11-15 CN CNA2006800509886A patent/CN101360833A/zh active Pending
- 2006-11-15 ES ES06808556T patent/ES2348607T3/es active Active
- 2006-11-15 NZ NZ568290A patent/NZ568290A/en not_active IP Right Cessation
- 2006-11-15 DK DK06808556.2T patent/DK1844164T3/da active
- 2006-11-15 BR BRPI0620507-0A patent/BRPI0620507A2/pt not_active IP Right Cessation
- 2006-11-15 PT PT06808556T patent/PT1844164E/pt unknown

Also Published As

Publication number	Publication date
BRPI0620507A2 (pt)	2011-11-16
NZ568290A (en)	2011-12-22
DK1844164T3 (da)	2010-11-01
PT1844164E (pt)	2010-10-12
CN101360833A (zh)	2009-02-04
GB0523250D0 (en)	2005-12-21

Publication	Publication Date	Title
RU2530550C2 (ru)	2014-10-10	Праймеры и зонды для детекции последовательностей вируса папилломы человека в исследуемых образцах
ES2581128T3 (es)	2016-08-31	Ensayo de mRNA de E6, E7 de HPV y métodos de empleo del mismo
US10988816B2 (en)	2021-04-27	Compositions and methods for detecting human papillomavirus nucleic acid
JP2005500856A (ja)	2005-01-13	多重フルオロフォアを使用する蛍光多重ｈｐｖｐｃｒアッセイ
AU2006205638A1 (en)	2006-07-20	Systems, methods, and compositions for detection of human papilloma virus in biological samples
CN107043828A (zh)	2017-08-15	一种高危人乳头瘤病毒分型检测方法与试剂盒
EP1844164B1 (en)	2010-07-14	Method of detecting pathogens using molecular beacons
KR100914911B1 (ko)	2009-08-31	실시간 중합효소 연쇄반응과 ｈｐｖｄｎａ 칩을 이용한정량 및 정성적 인유두종바이러스 검사 방법 및 이를 위한검사키트
JP5965846B2 (ja)	2016-08-10	近縁のヒトパピローマウイルス（ｈｐｖ）の血清型を検出するためのアッセイ
ES2348607T3 (es)	2010-12-09	Procedimiento de detección de patogenos con uso de balizas moleculares.
TWI757239B (zh)	2022-03-11	檢測ｈｐｖ之方法、擴增混合物及套組
Hamzan et al.	2021	Real-time loop-mediated isothermal amplification assay for rapid detection of Human Papillomavirus 16 in oral squamous cell carcinoma
WO2010033619A2 (en)	2010-03-25	Systems, methods, and compositions for detection of human papilloma virus in biological samples
US20060134615A1 (en)	2006-06-22	Method for the simultaneous detection of HPV RNA and DNA in a sample
MX2008006322A (es)	2008-09-26	Èmetodo para detectar patògenos
Khandan et al.	2025	Development of a Multiplex Taqman Real-time PCR method based on the E6 gene for detection of 31 and 33 HPV genotypes in women with cervical cancer
Andonovska	2011	THE FLUORESCENT IN SITU HYBRIDIZATION (FISH) IN THE DETECTION OF HUMAN PAPILLOMAVIRUS IN CERVICAL LESIONS
Enache et al.	2007	Human papillomaviruses and cervical cancer
AU2008212633A1 (en)	2008-08-14	Detection of human papillomavirus